Study Details
Full Title
Protocol NRG-GY035, A Randomized Phase III Trial of Carboplatin, Paclitaxel, and Pembrolizumab versus Carboplatin, Paclitaxel, and Bevacizumab versus Carboplatin, Paclitaxel, Pembrolizumab and Bevacizumab in the Treatment of PMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer (NCT07198074)
Principal Investigator
Angeles
Secord
Protocol Number
PRO00119814
NCT ID
NCT07198074
Phase
III
Enrollment Status
Open to Enrollment